摘要
目的比较三维适形放疗(3D-CRT)与调强放射治疗(IMRT)联合同步化疗治疗局部晚期宫颈癌(LACC)患者的临床疗效及安全性。方法将82例LACC患者随机分为3D-CRT组和IMRT组,每组41例。两组均给予紫杉醇联合卡铂方案化疗,3D-CRT组采用3D-CRT方案同步放疗,IMRT组采用IMRT方案同步放疗。比较两组患者治疗后8周的疗效、总生存期、无进展生存时间(PFS),以及急性和慢性放射反应发生率。结果两组患者的近期疗效、客观缓解率、疾病控制率、3年死亡率、中位PFS比较,差异均无统计学意义(均P>0.05)。3D-CRT组的急性、慢性放射反应总发生率及Ⅲ级放射反应发生率均高于IMRT组(均P<0.05)。结论3D-CRT或IMRT联合同步化疗治疗LACC的近远期临床效果相当,但IMRT的急慢性放射反应少于且轻于3D-CRT。
Objective To compare the clinical efficacy and safety of three-dimensional conformal radiotherapy(3 D-CRT)versus intensity-modulated radiation therapy(IMRT)in combination with concurrent chemotherapy for patients suffering from locally advanced cervical cancer(LACC).Methods Eighty-two LACC patients were randomly divided into 3 D-CRT group and IMRT group,with 41 cases in each group.Both groups were given chemotherapy of paclitaxel combined with carboplatin;besides,the 3 D-CRT group used 3 D-CRT for concurrent radiotherapy,and the IMRT group used IMRT for concurrent radiotherapy.The efficacy 8 weeks after treatment,overall survival(OS),progression-free survival(PFS),and the incidence rates of acute and chronic radiation reactions were compared between the two groups.Results There were no statistically significant differences between the two groups in shortterm efficacy,objective response rate,disease control rate,3-year mortality or median PFS(P>0.05).The 3 D-CRT groups exhibited a higher total incidence rate of acute or chronic radiation response,together with a higher incidence rate of gradeⅢradiation response as compared with the IMRT group(all P<0.05).Conclusions 3 D-CRT and IMRT in combination with concurrent chemotherapy are similar in short-and long-term clinical efficacy for LACC,but IMRT has less and milder acute/chronic radiation response than 3 D-CRT.
作者
朱锦贤
郭毅
邹元梅
ZHU Jin-xian;GUO Yi;ZOU Yuan-mei(Department of Oncologic Radiotherapy,Wuzhou Red Cross Hospital,Wuzhou 543002,China)
出处
《广西医学》
CAS
2019年第24期3122-3126,共5页
Guangxi Medical Journal
关键词
宫颈癌
局部晚期
三维适形放疗
调强放疗
同步化疗
疗效
安全性
Cervical cancer
Local advanced stage
Three-dimensional conformal radiotherapy
Intensitymodulated radiation therapy
Concurrent chemotherapy
Efficacy
Safety
